Marcus Koppitz

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

Antje M. Wengner, Gerhard Siemeister, Marcus Koppitz et al. · Molecular Cancer Therapeutics · 2016 · 118 citations · Full text

Medicine, Oncology, Pharmacology +17

Characterization of novel MPS1 inhibitors with preclinical anticancer activity

Mohamed Jèmaà, Lorenzo Galluzzi, Oliver Kepp et al. · Cell Death and Differentiation · 2013 · 111 citations · Full text

Medicine, Oncology, Pharmacology +14

Systematic Mutational Analysis of the Receptor‐Binding Region of the Human Urokinase‐Type Plasminogen Activator

Viktor Magdolen, P. Rettenberger, Marcus Koppitz et al. · European Journal of Biochemistry · 1996 · 72 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +11

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Ulrich Lücking, Lars Wortmann, Antje M. Wengner et al. · Journal of Medicinal Chemistry · 2020 · 71 citations · Full text

Medicine, Medicinal Chemistry, Oncology +13

Inhibition of the Interaction of Urokinase-Type Plasminogen Activator (uPA) with Its Receptor (uPAR) by Synthetic Peptides

Markus Bürgle, Marcus Koppitz, Christoph Riemer et al. · Biological Chemistry · 1997 · 65 citations

Life Sciences, Biochemistry, Cell Signaling +5